In a systematic review of studies investigating cannabis therapy for the treatment of chronic non-cancer pain (CNCP), evidence pointed to cannabinoids primarily effecting change with respect to neuropathy or MS-related pain. For CNCPs, it is unlikely that cannabinoids can be used as a single therapy, but rather in conjunction with other therapies. The quality of evidence in many of the studies reviewed was low, so further research needs to be completed in order to evaluate the efficacy of cannabinoids as a long-term treatment option for CNCPs.
CBD Shows Promise for Schizophrenia, Alzheimer’s, and Brain Injury Patients
A meta-analysis of previous studies investigating cannabidiol’s (CBD) potential to improve cognitive function among schizophrenia and brain injury patients offers hope to doctors and patients. In experiments on both human patients and rat models of schizophrenia, Alzheimer’s Disease, hypoxic-ischemic brain injury, hepatic encephalopathy, sepsis, pneumococcal meningitis, and cerebral malaria, the administration of CBD reduced neuroinflammation and resulting deficits in spatial learning and memory, recognition memory, and associative learning. Read more or download PDF on the CED Foundation Archive: http://bit.ly/2W1PpW8
In this same review, further investigating the effect of the non-psychoactive cannabidiol (CBD) on cognitive function suggests CBD counteracts the cognitive deficiencies induced by the psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC). Studies performed on humans and rat models demonstrated that CBD can improve episodic and recognition memory, verbal and visual learning and memory, and working memory, all skills which are usually impaired by THC content. For patients looking to reduce the aforementioned undesirable effects of cannabis, strains or products with high CBD and low THC content may be a viable solution.
Benjamin Caplan, MDA systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia